通心络胶囊对冠心病治疗效果的临床对照观察

目的观察通心络胶囊对冠心病（CHD）常见临床症状的改善效果。方法对照组维持原有药物治疗不变,治疗组在此基础上加服通心络胶囊4粒/次,3次/日,疗程4周。病人接受观察前进行常规化验检查,检测心率、血压、心功能等指标。疗程结束时对上述指标再进行检查,并观察病人的临床症状改善情况。结果两组病人的胸痛、胸闷、气憋、心悸、乏力等常见临床症状均有改善,且治疗组明显优于对照组（P〈0.05）;治疗组每搏量和心排血量的较对照组提高较为明显（P〈0.01）。结论加服通心络胶囊治疗CHD能增强西药的治疗效果,进一步改善CHD病人的常见临床症状。     

外周血及移植肾内嗜酸性粒细胞变化的临床意义

为了解移植肾在急性排斥时外周血和移植肾内嗜酸性粒细胞（ＥＯ）变化的意义，动态观察３１例同种异体肾脏移植病人的外周血和移植肾内ＥＯ的变化。结果发现在急性排斥反应时，移植肾内ＥＯ数＞２％者占８０．９％，明显高于肾功能稳定时，Ｐ＜０．０１；重度排斥中血ＥＯ数＞４％者占８２．６％，明显高于肾功能稳定时和中度以下排斥者，Ｐ＜０．０１。结果认为，测定移植肾内的ＥＯ变化可以做为监测急性排斥反应的可靠指标，外周血中的ＥＯ明显增多常提示排斥反应较为严重。     

X射线照射量(治疗水平)标准装置的研究和建立

Ｘ射线照射量（治疗水平）标准装置是由标准剂量仪，Ｘ射线照射源，测量车、定位系统及其辅助设备组成，本文作者主要介绍标准装置各个部分的构成及技术参数，该标准装置于１９９１年通过国家技术监督局认证，尔后，正式开展放射仪表的检定和校准工作。     

周围剂量当量仪的研制

周围剂量当量仪研制是根据国际辐射单位和测量委员会（ＩＣＲＵ）３９号报告推荐的周围剂量当量而设计的一种数字化智能型辐射防护仪。方法采用能量补偿对探测器进行能响校正。结果补偿结果使得探测器在４７～２３０ｋｅＶ与ＩＳＯ推荐的Ｈ＊（１０）／Ｋａ值误差在５％以内。本文重点描述了周围剂量当量仪探测器部分的工艺结构和剂量学性能以及电子学测量部分的主要功能。结论通过实际应用我们初步获得的结论是由于该仪器可直接测量周围剂量当量，稳定性好且具有自动取平均值特点，它可做为实验室校准用测量仪器，又由于该仪器体积小，电池供电，读数面板又有背光功能，它也可以做为现场仪器用于辐射防护实践的现场测量     

中重型β地中海贫血基因类型分析

目的 了解中间型和重型β地中海贫血基因突变类型及其相关血液，生化变化。方法 应用反向点杂交法检测16种β地贫点突变基因，常规进行血细胞分析及其他地贫筛查试验。结果 27例中重型β地贫患者中10例为纯合子，17例为双重杂合子，10例纯合子中5例CD41-42纯合子，占50%，3例TATAnt-28纯合子，占30%；CD17纯合子和IVS-nt654纯合子各1例，各占10%，17例双重杂合子中5例为IVS-nt654/CD41-42占29.4%,3例为CD17/CD41-42，占17.6%;3例为TATAnt-28/CD41-42，占17.6%;2例为βE/IVS-nt654,占11.6%;CD17/TATAnt-28,IVS-nt654/CD17,IVS-nt654/CD1-1,1CD71-72/IVS-nt654各1例，各占5.9%。27例患者血红蛋白均低于90.0g/L。平均为58.8g/L；平均MCV为65.0fl。脆性均少于60%。结论 中重型β地中海贫血基因突变类型多样，组合类型不同，临床表现轻重不一，多呈中重度贫血，血液，生化均有明显改变，多需输血维持生命，故应做好产前诊断，预防其出生。     

玻璃体切除术联合眼内填充治疗复杂性视网膜脱离

目的：讨论玻璃体切除术联合眼内C3F8或硅油填充治疗复杂性视网膜脱离的效果。方法：对61例(61眼)复杂性视网膜脱离患行玻璃体切除联合冷冻、惰性气体C3F8或硅油眼内充填治疗，术后密切观察随访6个月．结果；玻璃体切除联合冷冻、惰性气体C3F8或硅油眼内充填治疗术后视网膜解剖复位49例，其中行最后随访时的视网膜复位率80．3％。视网膜复位眼最后视力均有不同程度的提高。结论：玻璃体切除术联合眼内填充治疗复杂性视网膜脱离有良好的疗效，解除视网膜牵引及合理选择充填物是手术成功的关键。     

Species differences in platelet aggregation induced by platelet-activating factor (PAF).

Species differences in platelet aggregation induced by platelet-activating factor (PAF) were investigated by using the same procedure of platelet preparation and biological assay. Washed platelets of six different species (horses, dogs, rats, rabbits, sheep and guinea pigs) were prepared employing the same method and platelet aggregation was induced by C16-PAF. Horse platelets were most sensitive to PAF (8.0 x 10(-12) M) and rabbit platelets activated by 5.0 x 10(-11) M PAF were also sensitive enough to detect PAF in clinical samples.     

44Sacral extracorporeal magnetic stimulation is an effective treatment for pelvic floor dyssynergia; Comparative study with biofeedback therapy

Background: Recent development of extracorporeal magnetic stimulation (ECMS) which uses current‐changing magnetic fields allows the induction of electrical stimulation in the desired deep tissue. Recent study showed the sacral nerve stimulation reduces corticoanal excitability that may play a functional role in anal continence mechanisms. Preliminary study shows that ECMS of sacral nerve can modify pelvic floor function and expel rectal balloon in patients with pelvic floor dyssynergia (PFD). Aims: To evaluate the effect of ECMS compared with biofeedback therapy (BF) in patients with PFD. Methods and Materials: Thirty‐eight patients who fulfilled Rome II criteria for PFD by colon transit time and anorectal function tests, were randomly treated with 8 sessions of ECMS (2/weeks; n = 19) at prone position or BF (2/weeks; n = 19) at sitting position. Stimulation parameters were set at 50–80% of maximum intensity, 10 and 50 Hz frequency, 3 s burst length with 3 and 6 s off using arm‐typed stimulator (BioCom‐1000, Mcube Co., Korea). Symptom scores for constipation with/without anorectal function test were repeatedly measured after each treatment. Response was defined as 50% or more decreased symptom score after treatment (partial response: 30–50%, poor: <30%). Results: Fifteen patients (age 49.1 ± 13.4 years, mean ± SD; 4 men) completed 8 session of BF and 14 patients (54.5 ± 17.6 years, 3 men) completed 8 session of ECMS. Four patients of BF group discontinued treatment due to unsatisfactory therapeutic effect (n = 1) and withdrew consent (n = 3) and 5 patients of ECMS group discontinued treatment because of same reasons (n = 1, 4). Total symptom scores were significantly decreased after treatment of 8 session in both treatment groups (13.4 ± 6.6 vs. 4.3 ± 4.0 for BF, p = 0.009; 14.9 ± 5.6 vs. 3.4 ± 4.0 for ECMS, p < 0.001). Bowel movements per week were also significantly increased after treatment in both groups (median 2 vs. 7 for BF, p = 0.035; median 2 vs. 7 for ECMS, p = 0.008). Thirteen out of 15 patients showed response in BF group and 12 out of 14 showed good response in ECMS group. No adverse effects in both groups. Conclusions: ECMS is as effective as BF for the treatment of PFD. Long‐term effect of ECMS for the patients with pelvic floor dyssynergia need to be evaluated in the near future.     

红细胞同工酶ADA－EAP一AK_1同步电泳分型方法的建立

综合、改良了分别分型的方法，建立了红细胞同工酶ＡＤＡ一ＥＡＰ一ＡＫ１同步电泳分型方法，为ＡＤＡ，ＥＡＰ和ＡＫ１３种红细胞同工酶在法医学鉴定中更广泛的应用，提供了一种可靠、经济、实用的方法。